Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 13/20 | 0.60 |
| ▸ | RAB9A | P51151 | 13/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.60 |
| ▸ | TP53 | P04637 | 3/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.58 |
| ▸ | MEN1 | O00255 | 7/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | PKM | P14618 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4913013 | 0.77 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL4913015 | 0.77 | RAB9A (0.56) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL17664263 | 0.76 | CA12 (0.72) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL12204615 | 0.76 | MEN1 (0.62) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL19403216 | 0.76 | TRPV1 (0.60) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL17664216 | 0.76 | TRPV1 (0.62) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL17664478 | 0.75 | NPC1 (0.54) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL107421 | 0.75 | RAB9A (1.00) | NPC1RAB9ASMN1; SMN2TP53KMT2A | |
| SCHEMBL19398209 | 0.73 | CCR2 (0.57) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 | |
| SCHEMBL17664224 | 0.73 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2KMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-09-28 | — | — | US | disclosed |
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2017-09-28 | — | — | US | disclosed |
| WO-2016049774-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY (CA) | 2016-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273922-A1 | UREA AND BIS-UREA BASED COMPOUNDS AND ANALOGUES THEREOF USEFUL IN THE TREATMENT OF ANDROGEN RECEPTOR MEDIATED DISEASES OR DISORDERS | AR, UTS2R, SHBG | NPC1 2234/4885RAB9A 2608/4885SMN1; SMN2 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.